| |
PH (N = 12)
|
HFrEF (N = 10)
|
Normal (N = 10)
|
p-value
|
|---|
|
Age (years [IQR])
|
64.5 (47.5–70.5)
|
60.0 (53.0–65.0)
|
24.4 (21.7–26.3
|
<0.001
|
|
Gender (% female)
|
8 (66.7)
|
1 (10.0)
|
8 (80.0)
|
0.004
|
|
BMI (kg/m2 [IQR])
|
25.4 (23.0–29.3)
|
29.2 (26.0–32.7)
|
24.1 (21.2–26.3)
|
0.47
|
|
Ischemic HD (%)
|
1 (8.3)
|
8 (80.0)
|
0 (0.0)
|
<0.0001
|
|
Congenital HD (%)
|
1a (8.3)
|
1 (10.0)
|
0 (0.0)
|
1.0
|
|
DM (%)
|
2 (16.7)
|
3 (30.0)
|
0 (0.0)
|
0.23
|
|
OSA (%)
|
3 (25.0)
|
2 (20.0)
|
0 (0.0)
|
0.33
|
|
HIV (%)
|
2 (16.7)
|
0 (0.0)
|
0 (0.0)
|
0.31
|
|
CTEPH (%)
|
2 (16.7)
|
0 (0.0)
|
0 (0.0)
|
0.31
|
|
Medication-ERA
|
6 (50.0)
|
0 (0.0)
|
0 (0.0)
|
0.002
|
|
Medication-sildenafil
|
7 (58.3)
|
0 (0.0)
|
0 (0.0)
|
0.0003
|
|
Medication-PA
|
2 (16.7)
|
0 (0.0)
|
0 (0.0)
|
0.31
|
- Continuous variable are reported as median (IQR)
-
CTEPH chronic thromboembolic pulmonary hypertension, DM diabetes mellitus, ERA endothelin receptor antagonist, HD heart disease, HIV human immunodeficiency virus, OSA obstructive sleep apnea, PA prostacyclin analogue, TE thromboembolism
-
aThis patient has severe pulmonary hypertension resulting from late repair of a ventricular septal defect
